The 2022 Tandem Meetings | The potential of iNKTs in the treatment of hematological malignancies
Antonia Rotolo
• 6 May 2022
Antonia Rotolo, MD, PhD, University of Pennsylvania Veterinary School of Medicine, highlights the benefits of invariant natural killer T-cells (iNKTs) in the treatment of hematological malignancies. iNKTs can be manufactured as off-the-shelf products and do not cause graft-versus-host disease (GvHD). The manufacturing process in itself is simpler and cheaper compared to conventional T-cell and NK-cell therapies. In addition, iNKTs have the potential to induce a strong host immune response and are active in the immunosuppressive microenvironment of solid tumors. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
